Celltrion’s COVID-19 treatment substance shows efficacy

Celltrion's COVID-19 treatment substance shows efficacy


Celltrion Inc., a leading pharmaceutical firm in South Korea, said Friday that its coronavirus antibody treatment substance has shown treatment efficacy in clinical trials.

CT-P59 has been administered to 32 healthy volunteers who have not contracted COVID-19 since July after receiving approval for phase one trials from the Ministry of Food and Drug Safety.


See Also:   New virus cases bounce back to over 100 on clusters, untraceable cases

It marked the first time that a locally made genetic recombination antibody treatment material was given the green light to be used on people.

The pharmaceutical company said it will conduct second and third phase clinical trials afterward.

Recommended Korea Tour Packages


The ministry, which is pushing hard to have a locally made treatment drug, earlier said if all goes well, Celltrion could start mass producing the drug in the first half of 2021. The initial output could be for 5 million people.

See Also:   New virus cases in Korea stay under 300 for 2nd day; church-linked, untraceable cases still at large

Besides local testing, Celltrion also received approvals in seven countries, including Britain, to conduct clinical trials for its material.

SOURCE: The KoreaTimes

About the author

She is an operating manager of HaB Korea. Love Korea, Love travel :) HaB it your way!
Subscribe to Magazine HaB Korea via Email

Enter your email address to subscribe to our online Magazine HaB Korea and receive updates on the latest articles, events and special offers!

Thank you for subscribing. Please check your email and confirm your subscription.

Something went wrong.

Send this to a friend